← Leaderboards
Ann Richmond
Vanderbilt University
$15,857,391
Attributed
$16,210,710
Total exposure
12
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$27,602,025 · 10
VA$0 · 3
By mechanism
R01$15,518,964 · 5
U54$11,626,942 · 2
P30$451,119 · 2
R13$5,000 · 1
I01$0 · 2
IK6$0 · 1
Top collaborators
- Harold L Moses9 shared
- Tuya Pal3 shared
- Chi Yan2 shared
- Christine M. Lovly1 shared
Most similar at Vanderbilt University
Same institution · by research overlap
- Todd R Graham$10,608,745
- Lauren Parker Jackson$4,203,628
- Ethan Lee$10,580,105
- Terence S. Dermody$49,981,852
- Ege T Kavalali$13,464,974
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsClinical TrialsPathway InteractionsNeoplastic CellTumor GrowthGrowthMelanomaTumorMediatingImmuneResponseMutationCellsNeoplasm MetastasisResistanceEnvironmentInhibitor/AntagonistChemokineImmunotherapyExhibitsDesignAffectMouse ModelBase
Grant awards (94)
Combining Immune Therapy with Targeted Therapies to Improve Melanoma Survival$0
I01 · FY2025 · VA
New Strategies for Treatment of NRAS Mutant Melanoma after Progression on Immune Checkpoint Inhibitors$361,357
R01 · FY2024 · CA · contact PI
Optimizing Response to Immune Checkpoint Inhibitor Therapy for Breast Cancer: A Role for Inhibitors of the PI3K pathway$345,281
R01 · FY2024 · CA · contact PI
New Strategies for Treatment of NRAS Mutant Melanoma after Progression on Immune Checkpoint Inhibitors$380,325
R01 · FY2023 · CA · contact PI
Optimizing Response to Immune Checkpoint Inhibitor Therapy for Breast Cancer: A Role for Inhibitors of the PI3K pathway$356,184
R01 · FY2023 · CA · contact PI
BLR&D Merit Review Research Career Scientist (RCS) Award (IK6)$0
IK6 · FY2023 · VA · contact PI
Combining Immune Therapy with Targeted Therapies to Improve Melanoma Survival$0
I01 · FY2023 · VA · contact PI
New Strategies for Treatment of NRAS Mutant Melanoma after Progression on Immune Checkpoint Inhibitors$372,669
R01 · FY2022 · CA · contact PI
Optimizing Response to Immune Checkpoint Inhibitor Therapy for Breast Cancer: A Role for Inhibitors of the PI3K pathway$356,184
R01 · FY2022 · CA · contact PI
Combining Immune Therapy with Targeted Therapies to Improve Melanoma Survival$0
I01 · FY2022 · VA · contact PI
BLR&D Merit Review Research Career Scientist (RCS) Award (IK6)$0
IK6 · FY2022 · VA · contact PI
New Strategies for Treatment of NRAS Mutant Melanoma after Progression on Immune Checkpoint Inhibitors$379,970
R01 · FY2021 · CA · contact PI
Optimizing Response to Immune Checkpoint Inhibitor Therapy for Breast Cancer: A Role for Inhibitors of the PI3K pathway$363,453
R01 · FY2021 · CA · contact PI
Cancer Research Career Enhancement and Related Activities$169,288
P30 · FY2021 · CA · contact PI
Combining Immune Therapy with Targeted Therapies to Improve Melanoma Survival$0
I01 · FY2021 · VA · contact PI
BLR&D Merit Review Research Career Scientist (RCS) Award (IK6)$0
IK6 · FY2021 · VA · contact PI
MMC, VICC, & TSU: PARTNERS IN ELIMINATING CANCER DISPARITIES (2 of 3)$1,107,640
U54 · FY2020 · CA
New Strategies for Treatment of NRAS Mutant Melanoma after Progression on Immune Checkpoint Inhibitors$392,929
R01 · FY2020 · CA · contact PI
Optimizing Response to Immune Checkpoint Inhibitor Therapy for Breast Cancer: A Role for Inhibitors of the PI3K pathway$376,492
R01 · FY2020 · CA · contact PI
Cancer Research Career Enhancement and Related Activities$187,391
P30 · FY2020 · CA · contact PI
Research Education Core$39,990
U54 · FY2020 · CA · contact PI
Combining Immune Therapy with Targeted Therapies to Improve Melanoma Survival$0
I01 · FY2020 · VA · contact PI
BLR&D Merit Review Research Career Scientist (RCS) Award (IK6)$0
IK6 · FY2020 · VA · contact PI
MMC, VICC, & TSU: PARTNERS IN ELIMINATING CANCER DISPARITIES (2 of 3)$1,083,735
U54 · FY2019 · CA
Improved therapy for p53wt melanoma by functionally restoring the CDKN2A pathway$361,688
R01 · FY2019 · CA · contact PI
Research Education Core$45,878
U54 · FY2019 · CA · contact PI
Combining Immune Therapy with Targeted Therapies to Improve Melanoma Survival$0
I01 · FY2019 · VA · contact PI
MMC, VICC, & TSU: PARTNERS IN ELIMINATING CANCER DISPARITIES (2 of 3)$1,232,910
U54 · FY2018 · CA
Improved therapy for p53wt melanoma by functionally restoring the CDKN2A pathway$372,875
R01 · FY2018 · CA · contact PI
Precision Smoking Treatment among Disabled Persons in the Southern Community Cohort Study$104,015
U54 · FY2018 · CA
Research Education Core$49,600
U54 · FY2018 · CA · contact PI
Research Education Core$11,556
U54 · FY2018 · CA · contact PI
Combining Immune Therapy with Targeted Therapies to Improve Melanoma Survival$0
I01 · FY2018 · VA · contact PI
MMC, VICC, & TSU: PARTNERS IN ELIMINATING CANCER DISPARITIES (2 of 3)$1,233,813
U54 · FY2017 · CA
Improved therapy for p53wt melanoma by functionally restoring the CDKN2A pathway$372,875
R01 · FY2017 · CA · contact PI
Chemokine Signals in the Premetastatic Niche Inhibit Metastasis$293,555
R01 · FY2017 · CA · contact PI
Research Education Core$49,601
U54 · FY2017 · CA · contact PI
Modeling New Therapeutic Approaches for Malignant Melanoma$0
I01 · FY2017 · VA · contact PI
MMC, VICC, & TSU: PARTNERS IN ELIMINATING CANCER DISPARITIES (2 of 3)$1,225,501
U54 · FY2016 · CA
Improved therapy for p53wt melanoma by functionally restoring the CDKN2A pathway$372,875
R01 · FY2016 · CA · contact PI
Chemokine Signals in the Premetastatic Niche Inhibit Metastasis$293,555
R01 · FY2016 · CA · contact PI
Research Education Core$39,002
U54 · FY2016 · CA · contact PI
Modeling New Therapeutic Approaches for Malignant Melanoma$0
I01 · FY2016 · VA · contact PI
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities ( 2 of 3)$664,819
U54 · FY2015 · CA
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities ( 2 of 3)$558,241
U54 · FY2015 · CA
Improved therapy for p53wt melanoma by functionally restoring the CDKN2A pathway$372,875
R01 · FY2015 · CA · contact PI
Chemokine Signals in the Premetastatic Niche Inhibit Metastasis$368,383
R01 · FY2015 · CA · contact PI
Modeling New Therapeutic Approaches for Malignant Melanoma$0
I01 · FY2015 · VA · contact PI
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities ( 2 of 3)$1,269,768
U54 · FY2014 · CA
Chemokine Signals in the Premetastatic Niche Inhibit Metastasis$353,230
R01 · FY2014 · CA · contact PI
Impact of IKKB and AurK Inhibitors on Host Immunity and Melanoma$318,507
R01 · FY2014 · CA · contact PI
Modeling New Therapeutic Approaches for Malignant Melanoma$0
I01 · FY2014 · VA · contact PI
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities ( 2 of 3)$800,339
U54 · FY2013 · CA
Chemokine Signals in the Premetastatic Niche Inhibit Metastasis$341,179
R01 · FY2013 · CA · contact PI
Impact of IKKB and AurK Inhibitors on Host Immunity and Melanoma$308,657
R01 · FY2013 · CA · contact PI
Targeting IKK beta and aurora kinases in melanoma$0
I01 · FY2013 · VA · contact PI
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities ( 2 of 3)$1,044,393
U54 · FY2012 · CA
Impact of IKKB and AurK Inhibitors on Host Immunity and Melanoma$328,358
R01 · FY2012 · CA · contact PI
Chemokine Receptor Studies: Defining the Dynamics of the Chemosynapse$287,011
R01 · FY2012 · CA · contact PI
Targeting IKK beta and aurora kinases in melanoma$0
I01 · FY2012 · VA · contact PI
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities ( 2 of 3)$1,066,141
U54 · FY2011 · CA
Impact of IKKB and AurK Inhibitors on Host Immunity and Melanoma$328,358
R01 · FY2011 · CA · contact PI
Chemokine Receptor Studies: Defining the Dynamics of the Chemosynapse$287,011
R01 · FY2011 · CA · contact PI
Impact of IKKB and AurK Inhibitors on Host Immunity and Melanoma$49,840
R01 · FY2011 · CA · contact PI
Targeting IKK beta and aurora kinases in melanoma$0
I01 · FY2011 · VA · contact PI
Chemokine Receptor Studies: Defining the Dynamics of the Chemosynapse$295,888
R01 · FY2010 · CA · contact PI
Impact of IKKB and AurK Inhibitors on Host Immunity and Melanoma$149,486
R01 · FY2010 · CA · contact PI
Chemokine Receptor Studies: Defining the Dynamics of the Chemosynapse$295,888
R01 · FY2009 · CA · contact PI
Targeting the NF-kappaB Pathway in Melanoma$287,454
R01 · FY2009 · CA · contact PI
Role of NIK Activation in Melanoma Progression$258,707
R01 · FY2009 · CA · contact PI
Chemokine Receptor Studies: Defining the Dynamics of the Chemosynapse$219,365
R01 · FY2009 · CA · contact PI
Targeting IKK beta and aurora kinases in melanoma$0
I01 · FY2009 · VA · contact PI
Chemokine Receptor Studies: Defining the Dynamics of the Chemosynapse$295,888
R01 · FY2008 · CA · contact PI
Targeting the NF-kappaB Pathway in Melanoma$287,454
R01 · FY2008 · CA · contact PI
Role of NIK Activation in Melanoma Progression$258,707
R01 · FY2008 · CA · contact PI
Targeting the NF-kappaB Pathway in Melanoma$287,454
R01 · FY2007 · CA · contact PI
Role of NIK Activation in Melanoma Progression$258,707
R01 · FY2007 · CA · contact PI
Targeting the NF-kappaB Pathway in Melanoma$295,074
R01 · FY2006 · CA · contact PI
Chemokine Receptor Studies$292,109
R01 · FY2006 · CA · contact PI
Role of NIK Activation in Melanoma Progression$265,567
R01 · FY2006 · CA · contact PI
Targeting the NF-kappaB Pathway in Melanoma$300,200
R01 · FY2005 · CA
Chemokine Receptor Studies$283,880
R01 · FY2005 · CA
Role of NIK Activation in Melanoma Progression$270,180
R01 · FY2005 · CA
Chemokine Receptor Studies$283,880
R01 · FY2004 · CA
Chemokine Receptor Studies$283,880
R01 · FY2003 · CA
Chemokines and Chemokine Receptors$5,000
R13 · FY2003 · AI
Chemokine Receptor Studies$283,880
R01 · FY2002 · CA
CORE--MOLECULAR GENETICS$4,550
P30 · FY2002 · AR
CHEMOKINE RECEPTOR STUDIES$247,447
R01 · FY2001 · CA
REGULATION OF EXPRESSION OF MGSA/GRO GENES IN MELANOMA$244,539
R01 · FY2001 · CA
CORE--MOLECULAR GENETICS$4,550
P30 · FY2001 · AR
CHEMOKINE RECEPTOR STUDIES$240,238
R01 · FY2000 · CA
REGULATION OF EXPRESSION OF MGSA/GRO GENES IN MELANOMA$237,416
R01 · FY2000 · CA
CORE--MOLECULAR GENETICS$85,340
P30 · FY2000 · AR